SciRhom Starts CMC Development of its First Drug Candidate for Clinical Development

SciRhom has taken the next step towards IND submission of the company’s first-in-class drug candidate for improved treatment of autoimmune diseases

MUNICH, Germany, April 11, 2022 / B3C newswire / -- SciRhom GmbH announced today that it has nominated the anti-iRhom2 antibody it will advance into clinical development. For this antibody, the company has closed an agreement with a top-tier biopharmaceutical manufacturer for the CMC development. This first-in-class drug candidate has demonstrated outstanding preclinical efficacy in treating rheumatoid arthritis (RA) and inflammatory bowel disease (IBD). Having completed the comprehensive characterization of the molecule, SciRhom will now enter into IND-enabling activities.

“We are very pleased with the latest progress we have made towards bringing this promising therapeutic concept closer to the clinic,” says Chief Executive Officer Dr. Jens Ruhe. “Our research and development team did a fantastic job in delivering this excellent molecule. The nominated antibody fulfills all attributes for a successful pharmaceutical development. We expect our clinical candidate to outperform standard of care medications and become an attractive treatment option for patients suffering from debilitating diseases.”

SciRhom’s drug candidate inhibits the cell surface-localized protein iRhom2, a critical regulator of the protease TACE (TNF-alpha-converting enzyme, ADAM17). By interfering with this complex, the anti-iRhom2 antibody allows the simultaneous blockade of several pro-inflammatory signaling pathways without impairing protective functions. The therapeutic relevance of SciRhom’s antibody may also extend beyond autoimmunity, as research evidence suggests potential benefits of iRhom2 inhibition for multiple therapeutic areas including inflammation, oncology, infectious and metabolic diseases.

About SciRhom GmbH
SciRhom GmbH, based in IZB Martinsried, Germany, is a biotech company that translates science into the preclinical and early clinical development of novel biopharmaceuticals for the treatment of life-threatening autoimmune diseases. Based on longstanding academic research conducted at Hospital for Special Surgery (HSS) and a well-established network of experts, SciRhom was founded in 2016 through a collaboration between academic and industry scientists with profound experience in antibody development. Since then, the company has developed first-in-class anti-iRhom2 antibodies and nominated a candidate for clinical studies. Four comprehensive patent families cover the company’s anti-iRhom2 antibodies and iRhom2-target epitopes, securing exclusivity and protection against me-too drugs. To date, SciRhom has successfully acquired seed funding from the High-Tech Gruenderfonds (HTGF), Hospital for Special Surgery, and other institutional and private investors.

Contact

SciRhom GmbH
Dr. Jens Ruhe
+ 49 (0)89 614 241 230
info@SciRhom.com

Keywords: Autoimmune Diseases; ADAM17 protein, human; Adam17 protein, mouse; iRhom2 protein; Tumor Necrosis Factor-alpha; Intracellular Signaling Peptides and Proteins; Signal Transduction; Antibodies, Monoclonal; Antibodies, Neutralizing; Arthritis, Rheumatoid; Lupus Erythematosus, Systemic; Inflammatory Bowel Diseases; Glomerulonephritis; Pharmaceutical Preparations; Biological Products; Germany

Published by B3C newswire